Erratum {#Sec1}
=======

After publication of our review \[[@CR1]\], we noted errors to the legend of Figure [1](#Fig1){ref-type="fig"}B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure [1](#Fig1){ref-type="fig"}, a corrected version of the original Figure [1](#Fig1){ref-type="fig"}).Figure 1**Dual blockade with antibody--drug conjugate and targeted therapy. (A)** SCID Beige mice were injected with 1 million cells per mouse in the estrogen receptor-positive, human epidermal growth factor receptor (HER)-positive cell line called BT474-m1. These animals were randomized into six groups and treated with: vehicle control; trastuzumab (5 mg/kg once weekly); lapatinib (100 mg/kg daily); ado-trastuzumab-emtansine (TDM-1; 5 mg/kg weekly); trastuzumab (5 mg/kg once weekly) + lapatinib (100 mg/kg daily); or TDM-1 (5 mg/kg weekly) + lapatinib (100 mg/kg daily). Tumor volume fold-change will be measured twice weekly post treatment. **(B)**, **(C)** BT474 and SKBR3 HER2-positive cell lines were treated with the following: vehicle control; TDM-1 (1 μg/ml); trastuzumab (10 μg/ml) + lapatinib (10 μM) 4); or TDM-1 (1 μg/ml) + lapatinib (10 μM). Cells were assessed for proliferation and apoptosis post treatment. \*Data analyzed by one way analysis of variance followed by Tukey analysis for a pairwise comparison of different groups, *P* \< 0.05. T, trastuzumab; L, lapatinib. Data from J Chang, unpublished data.
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